Skip to Main content Skip to Navigation
Conference papers

Parcours de médicaments produits industriellement à l'hôpital

Abstract : Private pharmaceutical companies account for the bulk of drug manufacturing today. However, alongside these medicines whose market introduction is governed by officially prescribed regulations, other forms of production, operating on a more restricted scale at the level of dispensaries and hospitals, also exist. Their output, labelled as "preparations" as opposed to speciality drugs, is in principle subject to fewer constraints. Such "preparations" were and continue to be made within a public industrial framework. Based on a study of industrially-produced drugs in the Paris Public Hospital administration, this paper will explore the reasons for and the stakes involved in state-controlled drug production in France as well as its recent evolution. An examination of the archives belonging to this institution as well as interviews with key actors allows us to apprehend several stages in the production of drugs by hospitals, this activity being related to the larger context of the evolution of the pharmaceutical industry, on the one hand, and hospitals on the other. The installation of industrial facilities within the contours of a public hospital system occurred progressively and took advantage of the prevailing circumstances: the presence of a centralised dispensary for the Paris hospitals, the rise in medicine consumption in hospitals during the 1960s, and the inability of the industry to respond to the specificities of this demand. Challenges to the production of drugs by a public institution as well as uncertainties surrounding this activity form part of its recent history while taking diverse forms and having various effects. In recent years, its normalisation via the adoption of the status of a pharmaceutical establishment and the renovation of the industrial infrastructure have been accompanied by a narrowing of its field of action with a focus on the manufacture of "orphan drugs", thus reinforcing its role as an auxiliary of private industry. At the same time, new forms of collaboration with private firms and, over and above the initiatives of the Central dispensary, new links between hospitals and the industry can be witnessed. In terms of the "pathway of medicines", these transformations have resulted in certain drugs being simultaneously produced by public and private entities, or transferred from a public production configuration to a private one or vice-versa with important consequences with respect to patients' access to medicines. The new public-private connections being forged, however, render more complex the pathways of certain drugs.
Document type :
Conference papers
Complete list of metadata
Contributor : Anne-Marie Arborio <>
Submitted on : Friday, November 19, 2010 - 4:55:30 PM
Last modification on : Tuesday, March 30, 2021 - 3:48:59 AM


  • HAL Id : halshs-00537941, version 1



Anne-Marie Arborio. Parcours de médicaments produits industriellement à l'hôpital. 3e congrès international « La Chaîne des médicaments », Sep 2009, Milan, Italie. ⟨halshs-00537941⟩



Record views